Recent studies have implicated the innate immunity system in the pathogenesis of myelodysplastic syndromes (MDS). Toll-like receptor (TLR) genes encode key innate immunity signal initiators. We recently identified multiple genes, known to be regulated by TLRs, to be overexpressed in MDS bone marrow (BM) CD34 þ cells, and hypothesized that TLR signaling is abnormally activated in MDS. We analyzed a large cohort of MDS cases and identified TLR1, TLR2 and TLR6 to be significantly overexpressed in MDS BM CD34 þ cells. Deep sequencing followed by Sanger resequencing of TLR1, TLR2, TLR4 and TLR6 genes uncovered a recurrent genetic variant, TLR2-F217S, in 11% of 149 patients. Functionally, TLR2-F217S results in enhanced activation of downstream signaling including NF-kB activity after TLR2 agonist treatment. In cultured primary BM CD34 þ cells of normal donors, TLR2 agonists induced histone demethylase JMJD3 and interleukin-8 gene expression. Inhibition of TLR2 in BM CD34 þ cells from patients with lower-risk MDS using short hairpin RNA resulted in increased erythroid colony formation. Finally, RNA expression levels of TLR2 and TLR6, as well as presence of TLR2-F217S, are associated with distinct prognosis and clinical characteristics. These findings indicate that TLR2-centered signaling is deregulated in MDS, and that its targeting may have potential therapeutic benefit in MDS.
INTRODUCTION
The myelodysplastic syndromes (MDS) are a complex group of malignant myeloid disorders arising from bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs). 1 The pathophysiology of MDS is not fully understood. We recently performed a genome-wide chromatin immunoprecipitation (CHIP)-Seq analysis of H3K4me3 in MDS. 2 This analysis identified multiple genes marked by increased H3K4me3 in BM CD34 þ cells. A large majority of the genes identified are known to be involved in Toll-like receptor (TLR)-mediated innate immunity signaling and NF-kB activation. 2 TLRs are a family of patternrecognition receptors that function as key initiators of innate immunity signaling. 3 In the same study, we also identified that the histone demethylase JMJD3 (KDM6B) is significantly overexpressed in MDS BM CD34 þ cells and has an important role in the regulation of expression of genes involved in innate immunity. 2 Prior work by De Santa et al. 4 in murine macrophages has indicated that JMJD3 expression is regulated by TLR-mediated NF-kB activation. These findings suggested a potential role for TLR function in MDS.
On the basis of these findings, we performed gene expression and mutational analysis of eight human TLRs in a large cohort of MDS. Several major findings are reported here. First, we identified that TLR1, TLR2 and TLR6 are significantly overexpressed in MDS BM CD34 þ cells. Of importance, both TLR1 and TLR6 are known to form functional heterodimers with TLR2. Second, deep sequencing identified a rare genetic variant of TLR2 (F217S) present in 11% of BM mononuclear cells (BM-MNCs) of patients with MDS. The incidence of TLR2-F217S in MDS is significantly higher than its known frequency in normal population. Third, we demonstrated that inhibition of TLR2 in cultured BM CD34 þ cells from patients with lower risk of MDS results in increased formation of erythroid colonies. Finally, clinical analysis indicated that RNA expression levels of TLR2 and TLR6, as well as the presence of TLR2-F217S, were associated with distinct clinical characteristics. These results indicate that TLR2-mediated innate immune signaling has a role in the pathophysiology of MDS, and that its targeting may have therapeutic potential.
MATERIALS AND METHODS

Isolation and culture of BM CD34 þ cells
Human samples were obtained following institutional guidelines. MDS BM specimens were freshly obtained from patients who were referred to the Department of Leukemia at MD Anderson Cancer Center following institutional guidelines. Diagnosis was confirmed by a dedicated hematopathologist (CB-R) as soon as sample was obtained. BMs from healthy individuals were obtained from AllCells (Emeryville, CA, USA). Isolation of CD34 þ cells was performed using MicroBead Kit (Miltenyi, Bergisch Gladbach, Germany). Primary BM CD34 þ cells were cultured in IMDM (Invitrogen, Carlsbad, CA, USA), 20% BIT 9500 (bovine serum albumin, insulin and transferin), human thrombopoietin 50 ng/ml, interleukin (IL)-3 10 ng/ml, stem cell factor 100 ng/ml, FLT3L 100 ng/ml (Stem Cell Technology, Vancouver, CA, USA). For colony-forming assays, healthy and MDS BM CD34 þ cells were seeded at 1000 and 10 000 cells per ml, respectively, in 3.5-cm round culture dishes with methocult GF H4434 (Stem Cell Technology).
Cell lines and culture 293T cells were cultured in DMEM, 10% fetal calf serum, 1% penicillinstreptomycin and 2 mM L-glutamine. OCI-AML3 cells were cultured in RPMI-1640, 10% fetal calf serum and 1% penicillin-streptomycin. All cells were obtained from American Type Culture Collection (Manassas, VA, USA).
Quantitative reverse transcription-PCR
Total cellular RNA was extracted using Trizol (Invitrogen) according to manufacturer's protocol. An amount of 200 ng of total RNA was used for reverse transcription (RT) reactions using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). For real-time PCR, primers and probes were purchased from Applied Biosystems and analyzed using an Applied Biosystems Prism 7500 Sequence Detection System. PCRs were performed using 20 Â Assays-On-Demand Gene Expression Assay Mix and TaqMan Universal PCR Master mix according to the manufacturer's protocol. GAPDH was used as the internal control.
Capture deep sequencing of genomic DNA Illumina paired-end libraries were generated according to the manufacturer's protocol (Illumina, San Diego, CA, USA). An amount of 3 mg of precaptured library DNA was used for each capture reaction. NimbleGen SeqCap EZ Hybridization and Wash Kits (Roche, Basel, Switzerland) were used following the manufacturer's protocol. A total of 14-17 cycles of PCR amplification were applied to the samples after hybridization, based on yield. After that, captured libraries were quantified by picogreen and sequenced on the Illumina HiSeq 2000 as 100-bp paired-end reads, following the manufacturer's protocols. Sequencing data were stored as fastq format that contained reads and quality information. Fastq files were then mapped and aligned to human reference hg18 using BurrowsWheeler Alignment Tool. 5 To refine the alignment and adjust the quality score provided by sequencer, GATK was used to realign reads and recalibrate the quality score. 6 Single-nucleotide polymorphism (SNPs) were called using AtlasSNP2 (http://www.biomedcentral.com/1471-2105/13/8). The posterior probability was set as 0.9 and the minimum number of variant reads as 3. To identify rare SNPs, candidate SNPs were filtered against dbSNP130, 1000 genome database and the Human Genome Sequencing Center (Baylor College of Medicine) internal database. Indels were called using AtlasIndel (http://www.hgsc.bcm.tmc.edu/cascade-techsoftware_atlas2_snp_indel_calling_pipeline-ti.hgsc).
Recombinant retrovirus-mediated short hairpin RNA transduction pGFP-V-RS plasmids expressing the 29mer short hairpin RNA (shRNA) against human TLR2 or control shRNA were purchased from Origene (Rockville, MD, USA). Recombinant retrovirus expressing shRNA was packaged in 293T cells (Invitrogen) and concentrated using the PEG-IT virus precipitation solution (System Biosciences, Mountain View, CA, USA). Transduction of OCI-AML3 and BM CD34 þ cells with virus was performed by mixing virus with cell suspension followed by centrifugation at 30 1C for 90 min with 4 mg/ml polybrene in medium. After viral transduction, OCI-AML3 cells with stable expression of the shRNA against TLR2 or a control scrambled shRNA were established in the presence of puromycine (10 mg/ml) in medium.
Luciferase assay 293T cells were transfected with pGL4.32[luc2P/NF-kB-RE] (Promega, Madison, WI, USA) or pAP1-Luc (Agilent, Santa Clara, CA, USA) together with pCMV6-AC-GFP-TLR2 wild-type (Origene) or P217S mutant. pRL-TK vectors expressing the Renilla luciferase were cotransfected as internal control. Lipofectamine 2000 (Invitrogen) was used for transfection. One day after transfection, TLR2 agonist MALP2 (1 mg/ml) or PAM2CSK4 (0.3 mg/ml; Invivogen, San Diego, CA, USA) were added to the medium. Luciferase assays were performed 8 h later with the Dual-Luciferase Reporter Assay kit (Promega) on 3010 luminometer (BD Biosciences, San Diego, CA, USA). Luciferase activity was calculated using the ratio of firefly luminescence from the pGL4.32[luc2P/NF-kB-RE] or pLuc-AP1 reporter to the renilla luminescence from the control pRL-TK vectors reporter.
Western blot and immunoprecipitation
293T cells were transfected with pCMV6-AC-GFP-TLR2 wild-type (Origene) or P217S mutant. TLR2 agonist MALP2 (1 mg/ml) or PAM2CSK4 (0.3 mg/ml; Invivogen) were added into the medium 1 day after transfection. Cells were collected after 5-30 min. Cells were lysed using RIPA lysis buffer (Cell Signaling, Danvers, MA, USA) or processed for immunoprecipitation using cross-link IP kit (Thermo Scientific, Rockford, IL, USA). Antibodies used include phospho-p38 and IRAK1 (4511 and 4504, Cell Signaling), phospho-IRAK1 (S376) (PAB0497, Abnova, Walnut, CA, USA), phospho-IRAK1 (T209) (ab61799, Abcam, Cambridge, MA, USA), polyUb-K63 (05-1308, Millipore, Billerica, MA, USA), TLR2 (TA306125, Origene) and b-actin (A5441, Sigma-Aldrich, St Louis, MO, USA).
Multicolor flow cytometry
All monoclonal antibodies, including CD34, CD117, CD64, CD14, CD71, CD45 and HLA-DR, were obtained from BD Biosciences (San Jose, CA, USA). Samples were incubated with monoclonal antibodies for 25 min at 4 1C and acquired on FACSCanto II instruments (BD Biosciences). Data were analyzed using FCS Express software (De Novo Software, Los Angeles, CA, USA).
CHIP-PCR
Immunoprecipitated DNA was analyzed by quantitative real-time PCR (qPCR) using the Quanti-Tect SYBR Green PCR kit (Qiagen, Valencia, CA, USA). The amount of DNA fragment co-precipitated with antibody was calculated and compared with the amount of the same genomic fragment in total input DNA, resulting in percent input.
Statistical methods
Overall survival (OS) was defined from date of sample to date of death or date last known alive; patients last known alive were censored for this analysis. To investigate associations between gene expression and OS, we considered splitting expression level at the 25th, 50th and 75th percentiles, generating three possible binary variables. Associations with clinical and demographical features at the time of sampling were assessed only at the median expression level. For ordered clinical features, such as International Prognostic Scoring System, the Kruskal-Wallis test was used; for binary features, such as gender, the Fisher's exact test was used. For continuous variables, such as percentage BM blasts or hemoglobin, the Wilcoxon rank sum test was used.
Other reagents Human lymphoblastoid cell DNA was purchased from Sigma-Aldrich. According to manufacturer's instructions, cells were collected from UK Caucasian blood donors. The DNA was then extracted from lymphoblastoid cell lines derived by Epstein Barr Virus that can be continuously propagated in culture.
RESULTS
Overexpression of TLR2 and its functional partners TLR1 and TLR6 in BM cells of MDS
We first profiled RNA expression of eight human TLRs (TLR1-4 and TLR6-9) in a cohort of MDS BM CD34 þ cells (N ¼ 40). RNA expression levels of TLRs in MDS in comparison with control BM CD34 þ cells are shown in Figure 1a . This initial analysis indicated that TLR1, TLR2 and TLR6 were significantly overexpressed in MDS samples compared with controls ( Figure 1a ). Although the expression of TLR4, TLR7, TLR8 and TLR9 was also increased in some MDS samples, the overall difference between MDS and controls was not significant (Figure 1a ). We then expanded the analysis of RNA expression of TLR 1, TLR2 and TLR6, and summarized their expression in total 103 cases of MDS BM CD34 þ samples analyzed. Summary of clinical characteristics of this sample cohort are in Supplementary Table 1 . Compared with controls, average expression levels in MDS samples were increased by 10-fold for TLR1 (74% over twofold increase, N ¼ 87, Po0.0001, Figure 1b ), by 37-fold for TLR2 (82% over twofold increase, N ¼ 83, Po0.0001, Figure 1c ) and by 168-fold for TLR6 (73% over twofold increase, N ¼ 94, P ¼ 0.0001, Figure 1d ). This result is of potential biological significance because both TLR1 and TLR6 are known to form functional heterodimers with TLR2. 7, 8 Identification of TLR2 mutation (F217S) in MDS BM-MNCs To further study the role of TLRs in MDS, we performed capture deep sequencing of genes encoding TLR1, TLR2, TLR4 and TLR6 in TLR2 in MDS Y Wei et al MDS BM-MNCs. We first studied a cohort of 40 patients and identified three rare SNP variants located in the coding region of TLR2 and one SNP in TLR4 (Supplementary Figure 1A) . We subsequently analyzed these four SNPs using Sanger sequencing. One rare TLR2 SNP (rs139227237, g.154624709T4C) was detected as a heterogeneous alteration in 11% (N ¼ 17) of a cohort of 149 MDS BM-MNC samples (Supplementary Table 2 and Figure 2a) . At the protein level, this SNP results in a conserved hydrophobic phenylalanine (F217) located in the leucine-rich repeats of extracellular region to be converted into a hydrophilic serine ( Figure 2b ). To evaluate whether TLR2-F217S is a somatic alteration in MDS, we analyzed the corresponding BM CD3 þ cells available from 16 of the 17 patients known to carry this alteration in BM-MNC. Fourteen of these patients did not carry F217S in CD3 þ cells (Figure 2a ). Of interest, two CD3 þ samples contained this SNP (Supplementary Figure 1B) . We also sequenced 20 CD3 þ samples isolated from patients without TLR2-F217S. No TLR2-F217S was detected in any of these CD3 þ cells (Supplementary Figure 1C) . We next analyzed a group of random normal control DNA samples (N ¼ 47) that were derived from human lymphoblastoid cells isolated from healthy donors. None of the normal control samples was positive for TLR2-F217S (data not shown).
Biological implications of TLR2-F217S in innate immunity signal activation To characterize the impact of TLR2 mutation F217S on the activation of innate immunity signaling, we expressed green fluorescent protein (GFP) fused with wild-type or TLR2-F217S in 293T cells (Figure 2c) , and analyzed NF-kB activity. 293T cells express endogenous TLR1 and TLR6 but not TLR2, and therefore are often used to characterize genetically altered forms of TLR2. 9 In luciferase reporter assays, in the absence of TLR2 agonist, expression of wild-type or F217S mutant TLR2 led to similar levels of NF-kB activation (Figure 2d ). When a TLR2 agonist (PAM2CSK4, PAM3CSK4 or MALP2) was added, NF-kB activation was increased in TLR2-F217S vs wild-type transfected cells (Figure 2d ). Similar effects on AP1 activity and associated phospho-p38MAPK were also observed in TLR2-F217S with PAM2CSK4 treatment but not without TLR2 agonist (Supplementary Figures 1D and 1E ). To further assess the effect of TLR2-F217S on innate immunity signaling, we examined the status of IRAK1 protein, a key downstream signal mediator of TLRs. 10 In the absence of TLR agonist, a slight increase of a slowly migrating IRAK1 band (B180 kDa) was observed in both wild-type and F217S-transfected 293T cells (Figure 2e ). After MALP2 and PAM2CSK4 treatment, the density of this high-molecular IRAK1 band was higher in TLR2 (F217S) than in wild-type transfected cells (Figure 2e ). IRAK1 immunoprecipitation followed by immunobloting indicated that this higher molecular form of IRAK1 contained phospho-and polyubiquitin-IRAK1 (Figure 2e ), two active isoforms of this protein. 11 Taken together, these results indicated that TLR2-F217S is a gain-of-function mutation that augments TLR2-mediated downstream signaling.
TLR2 stimulation in BM CD34 þ cells activates IL-8 and JMJD3 One major group of genes that are known to be regulated by TLR2 signals are inflammatory cytokines. 3 The levels of several of these cytokines are also known to be elevated in MDS BMs. 12, 13 We therefore investigated whether some of these cytokines were actively expressed in BM CD34 þ cells and whether deregulation of TLR2 in MDS BM CD34 þ cells could affect their expression. We first assessed the basal expression of several of these cytokines in normal BM CD34 þ cells. Results indicated that basal RNA level of IL-8 was significantly higher than that of other inflammatory cytokines analyzed, including IL-1B, IL-4, IL-6 and TNF-a We have recently identified that the histone demethylase JMJD3 is overxpressed in BM CD34 þ cells of MDS, which contributes to the abnormal epigenetic activation of multiple genes involved in innate immunity activation.
2 JMJD3 has been previously demonstrated to be regulated by TLRs in murine macrophages. 3 To examine if TLR2 activation can also activate JMJD3 in BM CD34 þ cells, we assessed the effects of MALP2 and PAM3CSK3 on the expression of JMJD3. Results indicated that in cultured BM CD34 þ cells, and in parallel to the increase in IL-8 expression, JMJD3 RNA levels also significantly increased after treatment with both TLR2 agonists (Figure 3b) . We previously reported that in OCI-AML3 cells, knockdown of JMJD3 negatively affects the expression of multiple innate immunity genes. 2 We therefore examined if IL-8 RNA expression was also altered in OCI-AML3 cell line that constitutively expresses an shRNA against JMJD3. In parallel to JMJD3 knockdown, we observed a decrease of IL-8 RNA (Figure 3c ). We next evaluated potential impact of JMJD3 knockdown on histone methylation by measuring the levels of H3K4me3 and H3K27me3 in the promoter of IL-8. CHIP-PCR revealed that there was a decrease in the level of H3K4me3 and an increase in the level of H3K27me3 in IL-8 promoter (Figures 3d and e) . These results indicated that TLR2 could activate the expression of both IL-8 and JMJD3. Furthermore, histone methylation of IL-8 promoter could be regulated by JMJD3. Consistent with the results from cultured cells, we also observed in primary MDS BM CD34 þ cells (N ¼ 42) that RNA levels of IL-8 and JMJD3 were both positively correlated with TLR2 expression (R ¼ 0.88 and 0.61, respectively, Po0.0001), and, furthermore, IL-8 level was also positively correlated with JMJD3 expression (R ¼ 0.66, Po0.0001).
TLR2 activation negatively regulates erythroid differentiation in cultured BM CD34 þ cells Stimulation of TLR2 has been shown to alter hematopoietic differentiation in cultured mouse HSPCs. 4 To explore the impact of TLR2 activation in human BM CD34 þ cells, we treated BM CD34 þ cells isolated from healthy individuals (N ¼ 4) with TLR2 agonists (MALP2 and PAM3CSK4) and analyzed their effects on hematopoietic differentiation: 48 h after treatment, flow cytometry assays indicated that MALP2 caused a significant decrease of a erythroid precursor cell population, which was defined by strong CD71 expression and absence of HLA-DR (Figures 4a and b) . PAM3CSK4 had similar but less significant effect (Figures 4a  and b) . The negative influence of TLR2 agonists on erythroid lineage was further confirmed by colony formation assays in methylcellulose medium (methocult). After 2 weeks in methocult culture, MALP2 treatment led to a 55% reduction in erythroid colony-forming units (CFU-E) (Figure 4c) . Consistent with the results of flow cytometry, PAM3CSK4 had a similar but less significant effect on CFU-E formation (Figure 4c ). We also assessed the impact of IL-8 treatment in colony formation of normal BM CD34 þ cells and observed similar negative effect on CFU-E formation as TLR2 agonist treatments (Figure 4c ).
Inhibition of TLR2 positively regulates CFU-E formation in MDS BM CD34 þ cells
To evaluate the effect of TLR2 inhibition on hematological colony formation in cultured MDS BM CD34 þ cells, we transduced primary BM CD34 þ cells isolated from patients with newly diagnosed lower-(N ¼ 4) and higher-risk MDS (N ¼ 3) with a recombinant retroviral-mediated shRNA against TLR2. Patients' characteristics are described in Supplementary Table 3 . TLR2-shRNA resulted in reduced levels of TLR2 RNA expression in primary MDS BM CD34 þ cells examined (Supplementary Figure 3A) . After 2 weeks of culture in methocult medium, all four lower-risk samples had an increased number of erythroid colonies (CFU-E) after TLR2-shRNA transduction (Figure 5a ). On average, 64 CFU-E were formed per 10 4 MDS BM CD34 þ cells plated in response to the transduction of TLR2-shRNA, which was a 35% increase compared with the number of CFU-E formed after control shRNA transduction (Figure 5a ). No significant effect on the formation of myeloid colonies (CFU-G/M) was observed after TLR2 inhibition (Figure 5a ). Representative images of the methocult colonies formed from one low-risk sample are shown in Figure 5b . In contrast to lower-risk MDS, we did not observe a positive effect on the formation of erythroid or myeloid colonies in any of the three BM CD34 þ cells isolated from patients with higher-risk MDS (Supplementary Figure 3B) . To further verify the effect of TLR2 inhibition in lower-risk samples, we measured transcripts of several genes known to be positively associated with erythroid differentiation, including Glycophorin-A (GYPA), CD71, EPOR and GATA1. In the cells collected from methocult colonies, expression of all four genes was increased after TLR2 inhibition (Figure 5c ). The effect on gene expression further confirmed the positive impact of TLR2 inhibition on the differentiation of erythroid lineage in MDS BM CD34 þ cells of lower-risk type of MDS.
Clinical implications of TLR in MDS
To further investigate implications of TLR1, TLR2 and TLR6 deregulation in MDS, we analyzed the associations of RNA expression in MDS BM CD34 þ cells (N ¼ 103) with relevant clinical characteristics. Increased levels of TLR2 expression were associated with low-risk MDS by International Prognostic Scoring System (P ¼ 0.01) (Figure 6a ), diploid cytogenetic (P ¼ 0.04) and a diagnosis of chronic myelomonocytic leukemia (P ¼ 0.04). In contrast, expression of TLR6 gradually increased with International Prognostic Scoring System risk: high-risk patients had highest TLR6 expression, intermediate-1 and -2 patients had intermediate expression and low-risk group had lowest TLR6 expression (P ¼ 0.015) (Figure 6b ). Patients that had lowest TLR6 expression were associated with diploid cytogenetic (P ¼ 0.02) and a diagnosis of chronic myelomonocytic leukemia (P ¼ 0.0004). 
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Furthermore, patients with higher TLR6 expression (above median) had increased percentage of BM blasts (7.8 vs 3.2%; Po0.0001). In terms of OS, we observed that patients with higher TLR2 expression (above 25% median) had significant longer survival than patients with lower TLR2 expression (43.9 vs 13.7 months; P ¼ 0.03; Figure 6c ). TLR6 expression had a tendency to be negatively correlated with OS (22.7 vs 72.8 months; P ¼ 0.18) (Figure 6d ). Finally, patients with TLR2-F217S had a significant higher frequency of chromosome 7 deletion (P ¼ 0.03; Figure 6e ).
DISCUSSION
Recent advance indicates that abnormal activation of innate immunity signals occurs in MDS. For instance, deregulation of TRAF-6, a key innate immunity signal mediator, together with the loss of miR-146a, is involved in the development of del5q MDS.
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We also recently reported that the histone demethylase JMJD3 and multiple innate immunity genes regulated by JMJD3 are overexpressed in BM CD34 þ cells of MDS. 2 Of importance, expression of JMJD3 has been previously shown to be controlled by TLR-mediated NF-kB activation in murine macrophage cells. 4 Based on this, we hypothesized that TLRs could be abnormally upregulated in MDS.
First, based on the analysis of RNA expression in a large cohort of patient samples, we document significant overexpression of TLR1, TLR and TLR6 in MDS BM CD34 þ cells. Although TLRs are known to be present in differentiated hematopoietic cells, such as macrophages and dendritic cells, emerging evidence has recently indicated that functional TLRs are also actively expressed in primitive HSPCs, including hematopoietic stem cells and their early progenies such as multipotent progenitors, common [16] [17] [18] It is known that both TLR1 and TLR6 bind to TLR2, 7, 8 and together they form TLR2-centered functional pattern-recognition receptor complexes that recognize conserved molecular patterns. These conserved molecular patterns are derived from Grampositive bacteria and mycobacteria or from endogenous molecules released during tissue damage or cell death. 3, 19, 20 Therefore, the identification of overexpression of TLR1, TLR2 and TLR6 in MDS BM CD34 þ cells is of potential biological significance. For instance, an autosomal syndrome with monocytopenia and increased susceptibility to mycobacteriosis has been reported in MDS.
21
TLR2 has been demonstrated to be overexpressed in other types of neoplasms and has been shown to have oncogenic function independent of chronic inflammation in a gastric cancer model. 22 Other studies using smaller patient cohorts have previously reported the overexpression of other TLRs such as TLR4 in MDS BM CD34 þ cells. 23 We have also identified a mutation of TLR2-F217S in 11% of patients. We demonstrate that TLR2-F217S induces more robust activation of NF-kB, p38MAPK and IRAK1 modifications upon stimulation with TLR2 agonists in transfected 293T cells (Figure 2 and Supplementary Figure 4) . These results are in support of the 24, 25 To further clarify this, we will need to analyze non-hematological controls, such as germline cells, in large cohort of patients. A potential model is that TLR2-F217S can not only be a somatic mutation in patients with MDS but also a polymorphism that could be associated with increased risk for development of MDS. Large-scale population analysis in both patients and healthy individuals, as well as detailed biological characterization in hematopoietic cells, will need to be performed to better define the implications of TLR2-F217S in the pathogenesis of MDS.
In this study, we also observed that stimulation of TLR2 in human BM CD34 þ cells leads to activation of multiple genes known to be overexpressed in the same cell compartment of MDS. Emerging evidence has recently suggested a direct regulation of HSPCs by innate immunity signaling. 26 In mouse HSPCs, acute TLR stimulation has been shown to alter myeloid/lymphoid ratios, whereas chronic stimulation results in stem cell exhaustion and BM failure. 16, 17 Hyperactivation of TLR signaling has also been documented in BM failure syndromes such as Fanconi anemia. 27, 28 In this report, we demonstrate that TLR2 activation in primary human BM CD34 þ cells activates expression of histone demethylase JMJD3 and the inflammatory cytokine IL-8. We also demonstrate that JMJD3 can positively regulate expression of IL-8. In a recent study, we have previously shown that JMJD3 activates expression of the gene encoding IL-8 receptor (IL8RB), which is overexpressed in MDS BM CD34 þ cells. 2 Together, these results suggest that in BM CD34 þ cells of MDS, there is a potential TLR2-JMJD3-IL-8 signaling axis. One molecular consequence of the deregulation of this signaling is overexpression IL-8. Overexpressed IL-8 then influences the fate of CD34 þ HSPCs through its receptor (IL8RB), which is overexpressed in the same cell, forming a potential autocrine of IL-8 to contribute to the pathogenesis of MDS (Figure 6f) .
Results of this study also have clinical implications. First, knockdown of TLR2 in MDS CD34 þ cells resulted in increased erythroid differentiation. Although the precise biochemical mechanisms by which TLR2 inhibition promotes erythroid differentiation is still unclear, these observations have obvious therapeutic implications, suggesting that targeting TLR2 could improve hematopoiesis in patients with MDS. Second, RNA expression levels of TLR2 and TLR6, as well as the presence of genetic alteration of TLR2-F217S, were associated with several important clinical characteristics. Of interest, there is a potential discrepancy between the effect of TLR2 and TLR6 expression. This discrepancy potentially reflects the pathological and molecular heterogeneity of MDS. Mechanistically, this discrepancy suggests that TLR6 can potentially contribute to the pathogenesis of MDS through mechanisms independent of its interaction with TLR2. Indeed, recent studies have suggested that TLR6 can interact with innate immunity receptors other than TLR2 to sense microbial invading and stimulate host-defensive response. 29 The results of clinical analysis should be considered exploratory and need to be validated in a larger cohort of patients.
In summary, this study identifies that a TLR2-centered innate immunity pathway is deregulated in MDS, including both gene overexpression and genetic alteration. These results, together with our recent identification of JMJD3 and other genes that are involved in innate immunity regulation, further support a role of innate immunity signals in the BM stem/progenitor cells of MDS.
Further characterization of TLR2-associated innate immunity signals, particularly the potential TLR2-JMJD3-IL-8 axis, may have prognostic and therapeutic benefits in MDS.
